ZJYL vs MPWR vs NVCR

For growth investors, Monolithic Power Systems, Inc.

(MPWR) is the stronger pick with 26. 4% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Jin Medical International Ltd. (ZJYL) offers the better valuation at 93. 6x trailing P/E, making it the more compelling value choice. Analysts rate Monolithic Power Systems, Inc. (MPWR) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Jin Medical International Ltd.

(ZJYL) is the cheapest at 93. 6x versus Monolithic Power Systems, Inc. at 123. 6x.

Over the past 5 years, Monolithic Power Systems, Inc.

(MPWR) delivered a total return of +366. 2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: MPWR returned +24. 9% versus ZJYL's -72. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Jin Medical International Ltd.

(ZJYL) is the lower-risk stock at 1. 57β versus Monolithic Power Systems, Inc. 's 2. 28β — meaning MPWR is approximately 45% more volatile than ZJYL relative to the S&P 500. On balance sheet safety, Monolithic Power Systems, Inc. (MPWR) carries a lower debt/equity ratio of 1% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Monolithic Power Systems, Inc.

(MPWR) is pulling ahead at 26. 4% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -65. 2% for Monolithic Power Systems, Inc.. Over a 3-year CAGR, MPWR leads at 15. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Monolithic Power Systems, Inc.

(MPWR) is the more profitable company, earning 22. 1% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 22. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MPWR leads at 26. 1% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

In this comparison, MPWR (0.

4% yield) pays a dividend. ZJYL, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Jin Medical International Ltd.

(ZJYL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Monolithic Power Systems, Inc. (MPWR) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ZJYL: -72. 3%, MPWR: +24. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZJYL (Healthcare) and MPWR (Technology) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZJYL is a small-cap high-growth stock; MPWR is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.